Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
Genmab A/SJanuary 26, 2021 GMT
Company Announcement
Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
Copenhagen, Denmark; January 26, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous formulation (sold under the tradename DARZALEX
FASPRO ® in the U.S.), as reported by Johnson & Johnson were USD 4,190 million in 2020. Net trade sales were USD 2,232 million in the U.S. and USD 1,958 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX and DARZALEX
Search jobs 19-Jan-2021 Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Company Announcement
®
(daratumumab and hyaluronidase-fihj) approved by U.S. FDA as the first and only therapy for newly diagnosed Light-chain (AL) amyloidosis
Accelerated approval of DARZALEX
Genmab to receive USD 30 million milestone payment on first commercial sale
Copenhagen, Denmark; January 15, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of DARZALEX